RxDoctor Payments Data

Kristin Wiese, MD

Pulmonary Disease · Naperville, ILNPI 1619103280

Payments from drug & device makers

$97in general payments, 2019–2025

Across 4 payments — averaging $24.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$34
  • Verona Pharma, Inc.$30
  • GSK$19
  • Philips North America LLC$14

What the payments were for

  • Food & beverage$6365%
  • Education$3435%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen1$34
Verona Pharma, Inc.1$30
GSK1$19
Philips North America LLC1$14

How this compares

$97 in reported general payments places this provider in the 15th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$376,627
Medicare patients
823
Services billed
6,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate16$406,079
Trelegy ElliptaFluticasone/Umeclidin/Vilanter259$383,192
NucalaMepolizumab31$147,327
Dupixent PenDupilumab25$108,987
Breo ElliptaFluticasone/Vilanterol108$85,347
Spiriva RespimatTiotropium Bromide42$50,813
Advair HfaFluticasone Propion/Salmeterol59$43,844
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$22,580
SymbicortBudesonide/Formoterol Fumarate42$16,918
Fluticasone-SalmeterolFluticasone Propion/Salmeterol55$12,620
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$11,692
Albuterol Sulfate HfaAlbuterol Sulfate297$10,646
Arnuity ElliptaFluticasone Furoate13$8,480
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate25$7,629
DuleraMometasone/Formoterol22$7,626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$19$646,926440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →